Sponsored By
This activity is supported by an educational grant from Merck & Co.
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Use of Biosimilars in the Management of Rheumatologic and Gastrointestinal Diseases
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
Biosimilars represent new options for the management of patients with rheumatologic and gastrointestinal diseases. The nature of biosimilars and the ways in which they should be used in clinical practice can be confusing to clinicians. An improved understanding of these agents will help to optimize the use of biosimilars.Learning Objectives
After completing this continuing education activity you will be able to:
- Differentiate between biosimilar drugs and generic (bioequivalent) drugs.
- Identify FDA's basis for licensure of biosimilars.
- Identify available biosimilars indicated for rheumatologic and gastrointestinal disorders.
- Indicate how biosimilars should be used in clinical practice.
Disclosures
All faculty and planners have disclosed that they have no relationships relevant, financial or otherwise relevant to this learning activity. This activity is provided by Lippincott Professional Development, and jointly provided by Lippincott Continuing Medical Education Institute, Inc., and American Academy of PAs.
Price:
FREE
Credits:
- ANCC 0.75 CH / 0.75 APH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Awarded Advanced Pharmacology Hours
Awarded Advanced Pharmacology Hours
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: BRG0918
Published: September 2018
Expires: 12/31/2026
Required Passing Score: 4/5 (80%)
Categories:
Advanced Practice Nursing
,
Pharmacology
Specialties:
Gastroenterology,
Rheumatology
Topics:
Biosimilars